Ekso Bionics Holdings Inc (NASDAQ:EKSO) was the target of a large increase in short interest in October. As of October 31st, there was short interest totalling 3,460,000 shares, an increase of 9.1% from the September 30th total of 3,170,000 shares. Approximately 4.7% of the shares of the company are sold short. Based on an average daily trading volume, of 491,600 shares, the short-interest ratio is currently 7.0 days.
Several institutional investors and hedge funds have recently made changes to their positions in EKSO. Wells Fargo & Company MN raised its position in Ekso Bionics by 4,401.9% in the second quarter. Wells Fargo & Company MN now owns 49,521 shares of the company’s stock worth $63,000 after purchasing an additional 48,421 shares in the last quarter. CVI Holdings LLC acquired a new stake in shares of Ekso Bionics during the second quarter worth approximately $494,000. BlackRock Inc. increased its holdings in shares of Ekso Bionics by 123.2% during the second quarter. BlackRock Inc. now owns 813,996 shares of the company’s stock worth $1,035,000 after buying an additional 449,348 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Ekso Bionics by 41.2% during the second quarter. Vanguard Group Inc. now owns 2,085,186 shares of the company’s stock worth $2,648,000 after buying an additional 608,759 shares in the last quarter. Finally, Wasatch Advisors Inc. acquired a new stake in shares of Ekso Bionics during the second quarter worth approximately $2,398,000. 36.42% of the stock is owned by institutional investors and hedge funds.
Ekso Bionics stock traded up $0.01 during midday trading on Friday, reaching $0.55. The stock had a trading volume of 156,200 shares, compared to its average volume of 483,092. The company has a debt-to-equity ratio of 0.28, a quick ratio of 1.69 and a current ratio of 2.11. Ekso Bionics has a twelve month low of $0.48 and a twelve month high of $2.55. The stock’s 50-day simple moving average is $0.58 and its 200 day simple moving average is $1.04. The stock has a market capitalization of $41.29 million, a PE ratio of -1.25 and a beta of 1.60.
Ekso Bionics (NASDAQ:EKSO) last released its quarterly earnings results on Wednesday, October 30th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.07) by $0.01. Ekso Bionics had a negative net margin of 100.36% and a negative return on equity of 376.63%. The company had revenue of $3.32 million during the quarter. Equities analysts predict that Ekso Bionics will post -0.3 earnings per share for the current fiscal year.
Several equities analysts have weighed in on the company. Zacks Investment Research raised Ekso Bionics from a “hold” rating to a “buy” rating and set a $0.75 price target for the company in a research report on Wednesday, November 6th. ValuEngine cut Ekso Bionics from a “hold” rating to a “sell” rating in a report on Friday, November 1st. HC Wainwright began coverage on Ekso Bionics in a report on Monday, October 28th. They set a “buy” rating and a $1.20 price objective on the stock. Aegis restated a “buy” rating and set a $2.90 price objective on shares of Ekso Bionics in a report on Thursday, August 8th. Finally, Cantor Fitzgerald began coverage on Ekso Bionics in a report on Friday, September 6th. They set an “overweight” rating and a $1.00 price objective on the stock. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. Ekso Bionics has a consensus rating of “Buy” and an average price target of $1.46.
About Ekso Bionics
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America, Europe, the Middle East, and Africa. The company operates through EksoHealth and EksoWorks segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries and hemiplegia due to stroke.
Featured Story: Trading based on a resistance level
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.